Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Furegrelate
Cat. No.:
0225LY-0870
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
FUREGRELATE functions as an inhibitor of thromboxane A2 (TxA2) synthase and has been shown to reduce the progression of pulmonary arterial hypertension in neonatal pig models.
Synonym:
85666-24-6; Furegarelatum; Furegrelato; 5-(pyridin-3-ylmethyl)benzofuran-2-carboxylic acid; 5-(pyridin-3-ylmethyl)-1-benzofuran-2-carboxylic acid; 2-Benzofurancarboxylic acid, 5-(3-pyridinylmethyl)-; U-63557A (free acid); 5-(3-pyridylmethyl)-2-benzofurancarboxylic acid; 5-(3-Pyridinylmethyl)-2-benzofurancarboxylic acid; 5-(3'-Pyridinylmethyl)benzofuran-2-carboxylate sodium; Sodium 5-(3-pyridinylmethyl)-2-benzofurancarboxylate
CAS No.:
85666-24-6
Compound CID:
3437
Formula:
C15H11NO3
Formula Weight:
253.25
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Furegrelate can be used in cardiovascular studies to investigate the selective inhibition of thromboxane A2 synthase.
Library Information
Target:
TXAS
Receptor:
TXA2R
Pathways:
Metabolism; DNA damage/DNA repair
Plate Number:
AOCL-12
Plate Location:
b9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 197.43 mM
